Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -8.14
- Piotroski Score 1.00
- Grade Buy
- Symbol (ABEO)
- Company Abeona Therapeutics Inc.
- Price $5.99
- Changes Percentage (3.45%)
- Change $0.2
- Day Low $5.76
- Day High $6.17
- Year High $9.01
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 03/31/2000
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 03/17/2025
- Fiscal Year End N/A
- Average Stock Price Target $6.00
- High Stock Price Target $6.00
- Low Stock Price Target $6.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.15
- Trailing P/E Ratio -1.36
- Forward P/E Ratio -1.36
- P/E Growth -1.36
- Net Income $-54,188,000
Income Statement
Quarterly
Annual
Latest News of ABEO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Institutional investors own a significant stake of 39% in Abeona Therapeutics Inc. (NASDAQ:ABEO)
Institutional investors hold a significant stake in Abeona Therapeutics, influencing the stock's performance. Ownership structure reveals institutions own 39%, followed by hedge funds. Analysts and in...
By Yahoo! Finance | 4 months ago -
ABEO Stock Price | Abeona Therapeutics Inc. Stock Quote (U.S.: Nasdaq) | MarketWatch
Abeona Therapeutics is a biopharmaceutical company developing gene therapy for rare diseases. Their programs include treatments for recessive dystrophic epidermolysis bullosa and Sanfilippo syndromes....
By MarketWatch | 4 months ago -
Insider Sale: Director Christine Silverstein Sells Shares of Abeona Therapeutics Inc (ABEO)
Christine Silverstein, Director of Abeona Therapeutics Inc, sold 25,821 shares, now owning 62,063 shares. Abeona focuses on gene therapies for rare genetic diseases like EB-101 and ABO-102....
By Yahoo! Finance | 5 months ago
